Background Image
Table of Contents Table of Contents
Previous Page  595 / 1498 Next Page
Information
Show Menu
Previous Page 595 / 1498 Next Page
Page Background

follicular lymphoma responding to

rituximab

plus chemotherapy

(PRIMA): a phase 3, randomised controlled trial.

Salles G et al

Lancet. 2011 Jan 1;377(9759):42-51

stratified HR=0.50

95% CI 0.39; 0.64

p

<.0001

Time (months)

Rituximab maintenance

N=505

Observation

N=513

6

0

12

18

24

30

36

Progression-free rate

0.8

0.6

0.4

0.2

0

1.0

82%

66%

Patients at risk

505

513

472

443

336

230

103

18

469

411

289

195

82

15